Catalyst

Slingshot members are tracking this event:

Amgen (AMGN) and UCB Announce Phase III FRAME Results Evaluating Romosozumab in Postmenopausal Women with Osteoporosis

Source Link:
http://www.amgen.com/media/news-releases/2016/09/results-from-phase-3-frame-study-of-romosozumab-showed-significant-reductions-in-both-new-vertebral-and-clinical-fractures-in-postmenopausal-women-with-osteoporosis/

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
AMGN
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Sep 18, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase Iiii Frame Results, Romosozumab, Postmenopausal Women, Osteporosis
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.